FindTrial
Sign In

Effect of dapaglifozin on serum magnesium in HNF1β patients with renal hypomagnesemia

Effect of dapaglifozin on serum magnesium in HNF1β patients with renal hypomagnesemia - DAPA-MAG

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51437
Enrollment
12
Registered
2022-03-16
Start date
2023-05-31
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADTKD-HNF1&beta

Interventions

Dapagliflozin 10 mg or placebo tablet, one tablet per day. Participants will receive dapagliflozin during one period and placebo during the other period.

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Genetically proven ADTKD-HNF1β disease - Renal hypomagnesemia (serum magnesium

Exclusion criteria

Exclusion criteria: - All other types of diabetes mellitus, including type 1 and type 2 diabetes - History of kidney transplantation - Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolment - Previous intolerance for an SGLT2 inhibitor - Pregnancy or lactation - Use of loop diuretics or thiazide diuretics and inability to discontinue these medications before start of the trial - eGFR

Design outcomes

Primary

MeasureTime frame
Change in serum magnesium—

Secondary

MeasureTime frame
- Renal fractional magnesium excretion - Magnesium supplementation requirement - Symptoms scored by symptom questionnaire—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)